FDA Clears In-Vivo Gene Editing Therapy for Trial
The U.S. Food and Drug Administration has cleared Precision BioSciences’ investigational new drug application for PBGENE-DMD. The therapy is an in-vivo gene editing candidate for treating Duchenne Muscular Dystrophy. This clearance allows the company to proceed with clinical trials, marking a step forward for the in-vivo gene editing field.
- The therapy utilizes Precision BioSciences’ proprietary ARCUS® genome editing platform, which is based on the I-CreI homing endonuclease, a naturally occurring enzyme. Unlike CRISPR, ARCUS is a smaller, single-protein system that does not require a guide RNA, which simplifies the delivery process. - PBGENE-DMD employs a gene excision mechanism, using two ARCUS nucleases delivered by a single Adeno-Associated Virus (AAV) vector to remove a mutated "hot-spot" region of the dystrophin gene (exons 45-55). This approach is designed to restore the natural production of a near full-length, functional dystrophin protein, differentiating it from micro-dystrophin gene replacement therapies. - The Phase I/II clinical study, named FUNCTION-DMD, will evaluate the therapy's safety, tolerability, and efficacy in ambulatory patients. Activation of the first clinical trial site in the U.S. is anticipated in the first half of 2026. - A key aspect of the therapy's potential for long-term benefit is its demonstrated ability in preclinical models to edit satellite muscle stem cells. This suggests the genetic correction could be permanent and self-renewing within the muscle tissue, a potential advantage over non-editing gene therapies where expression can wane. - The use of an AAV vector places this therapy within a manufacturing paradigm with known challenges, including production scalability, achieving high functional titers, and managing the ratio of full to empty capsids, all of which are critical process considerations in a GMP environment. - This gene editing candidate enters a competitive landscape for Duchenne treatment that includes approved exon-skipping drugs and Sarepta’s gene replacement therapy, Elevidys. The global DMD therapeutics market is projected to see substantial growth, potentially reaching over $7 billion by 2030, driven by the commercialization of such novel gene therapies.
